Telix Pharmaceuticals |
Market Cap (5-Aug) $4,881,777,152 (204th) |
Close (30-Jun) $11.22 |
Volume (30-Jun) 664,557 |
Shortsold (30-Jul) 39,831,980 (11.72%) (8th) |
|
52w High $19.07 |
52w Low $8.26 |
P/E 250.00 |
EPS -0.03 |
[ARTICLE] Telix boss says Australia ‘horrible’ at getting drugs to patients
A news article has been posted about Telix Pharmaceuticals on the AFR. The article was published around , on 28 October 2024 at 2:26am.
Gift 5 articles to anyone you choose each month when you subscribe. Christian Behrenbruch, the co-founder and chief executive of $7 billion cancer diagnostic giant Telix Pharmaceuticals, has lashed out at Australia’s ability to make next-generation drugs ...
Read ArticleTLX was $11.22 at the close of trade on 30 June 2023
| Recent Articles about ASX:TLX | |
|---|---|
| 21-Jul | Notice of change of interests of substantial holder - AFR
company-announcements.afr.com |
| 21-Jul | Q2 Business Update - Telix Pharmaceuticals Limited
company-announcements.afr.com |
| 19-Jul | Appendix 3H - Notification of cessation of securities - AFR
company-announcements.afr.com |
| 17-Jul | Appendix 3G - Notification of issue, conversion or payment up ... - AFR
company-announcements.afr.com |
| 4-Jul | Q1 2026 Strong Revenue Growth and Tx Pipeline Advancement
company-announcements.afr.com |
| 3-Jul | 604 Page 1 of 6 - Market Index
company-announcements.afr.com |
| 3-Jul | Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain ...
company-announcements.afr.com |
| 2-Jul | FDA Alignment to Advance ProstACT Global Phase 3 Trial - AFR
company-announcements.afr.com |
| 1-Jul | Notice of change of interests of substantial holder - AFR
company-announcements.afr.com |
| 23-Jun | Notice of ceasing to be a substantial holder - AFR
company-announcements.afr.com |
| Tracked |
Find all articles about Telix Pharmaceuticals, including others on the AFR, on the media page.
You must be logged in to post a reply.